vs

Side-by-side financial comparison of GCT Semiconductor Holding, Inc. (GCTS) and HCW Biologics Inc. (HCWB). Click either name above to swap in a different company.

GCT Semiconductor Holding, Inc. is the larger business by last-quarter revenue ($758.0K vs $394.8K, roughly 1.9× HCW Biologics Inc.). HCW Biologics Inc. runs the higher net margin — -854.4% vs -1189.6%, a 335.2% gap on every dollar of revenue. On growth, GCT Semiconductor Holding, Inc. posted the faster year-over-year revenue change (-57.5% vs -70.2%). HCW Biologics Inc. produced more free cash flow last quarter ($-2.9M vs $-8.5M). Over the past eight quarters, HCW Biologics Inc.'s revenue compounded faster (-45.8% CAGR vs -58.8%).

GCT Semiconductor Holding, Inc. designs, develops and supplies high-performance wireless semiconductor solutions. Its product portfolio includes 4G LTE, 5G and IoT connectivity chips tailored for consumer electronics, industrial devices and telecom equipment. The company serves customers across North America, Asia-Pacific and European markets, with core segments covering mobile communications and edge connected devices.

HCW Biologics Inc. is a clinical-stage biotechnology company focused on researching and developing novel immunotherapies and biological products targeting unmet medical needs in oncology, chronic inflammatory disorders, and autoimmune diseases. It primarily operates in the U.S., advancing multiple pipeline candidates through early to mid-stage clinical trials.

GCTS vs HCWB — Head-to-Head

Bigger by revenue
GCTS
GCTS
1.9× larger
GCTS
$758.0K
$394.8K
HCWB
Growing faster (revenue YoY)
GCTS
GCTS
+12.6% gap
GCTS
-57.5%
-70.2%
HCWB
Higher net margin
HCWB
HCWB
335.2% more per $
HCWB
-854.4%
-1189.6%
GCTS
More free cash flow
HCWB
HCWB
$5.5M more FCF
HCWB
$-2.9M
$-8.5M
GCTS
Faster 2-yr revenue CAGR
HCWB
HCWB
Annualised
HCWB
-45.8%
-58.8%
GCTS

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
GCTS
GCTS
HCWB
HCWB
Revenue
$758.0K
$394.8K
Net Profit
$-9.0M
$-3.4M
Gross Margin
-162.7%
20.0%
Operating Margin
-1577.0%
-795.9%
Net Margin
-1189.6%
-854.4%
Revenue YoY
-57.5%
-70.2%
Net Profit YoY
-81.4%
68.4%
EPS (diluted)
$-0.16
$-10.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GCTS
GCTS
HCWB
HCWB
Q4 25
$758.0K
Q2 25
$1.2M
Q4 24
$1.8M
$394.8K
Q3 24
$2.6M
$426.4K
Q2 24
$1.5M
$618.9K
Q1 24
$3.3M
$1.1M
Q4 23
$4.2M
$1.3M
Q3 23
$4.5M
$853.1K
Net Profit
GCTS
GCTS
HCWB
HCWB
Q4 25
$-9.0M
Q2 25
$-13.5M
Q4 24
$-5.0M
$-3.4M
Q3 24
$-7.1M
$-3.9M
Q2 24
$-1.0M
$-15.3M
Q1 24
$757.0K
$-7.5M
Q4 23
$-10.2M
$-10.7M
Q3 23
$-4.3M
$-4.9M
Gross Margin
GCTS
GCTS
HCWB
HCWB
Q4 25
-162.7%
Q2 25
32.0%
Q4 24
32.3%
20.0%
Q3 24
62.3%
20.0%
Q2 24
62.7%
29.2%
Q1 24
59.8%
54.6%
Q4 23
44.3%
19.1%
Q3 23
11.8%
20.5%
Operating Margin
GCTS
GCTS
HCWB
HCWB
Q4 25
-1577.0%
Q2 25
-642.3%
Q4 24
-412.7%
-795.9%
Q3 24
-226.5%
-864.1%
Q2 24
-482.2%
-2445.8%
Q1 24
-665.1%
Q4 23
-102.9%
-813.3%
Q3 23
-89.7%
-595.2%
Net Margin
GCTS
GCTS
HCWB
HCWB
Q4 25
-1189.6%
Q2 25
-1145.3%
Q4 24
-278.5%
-854.4%
Q3 24
-272.8%
-915.1%
Q2 24
-71.0%
-2469.1%
Q1 24
23.2%
-662.8%
Q4 23
-242.6%
-806.7%
Q3 23
-97.1%
-578.9%
EPS (diluted)
GCTS
GCTS
HCWB
HCWB
Q4 25
$-0.16
Q2 25
$-0.26
Q4 24
$-0.15
$-10.47
Q3 24
$-0.16
$-4.13
Q2 24
$-0.02
$-16.16
Q1 24
$0.03
$-0.20
Q4 23
$-0.43
$-0.30
Q3 23
$-0.18
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GCTS
GCTS
HCWB
HCWB
Cash + ST InvestmentsLiquidity on hand
$590.0K
$4.7M
Total DebtLower is stronger
$62.6M
$7.4M
Stockholders' EquityBook value
$-83.3M
$-6.8M
Total Assets
$15.6M
$30.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GCTS
GCTS
HCWB
HCWB
Q4 25
$590.0K
Q2 25
$1.3M
Q4 24
$1.4M
$4.7M
Q3 24
$1.8M
$998.2K
Q2 24
$4.0M
$1.2M
Q1 24
$16.1M
$4.1M
Q4 23
$258.0K
$3.6M
Q3 23
$212.9K
$11.2M
Total Debt
GCTS
GCTS
HCWB
HCWB
Q4 25
$62.6M
Q2 25
$51.7M
Q4 24
$42.6M
$7.4M
Q3 24
$41.8M
$6.5M
Q2 24
$43.6M
$9.9M
Q1 24
$50.5M
$8.3M
Q4 23
$79.9M
$6.3M
Q3 23
$6.3M
Stockholders' Equity
GCTS
GCTS
HCWB
HCWB
Q4 25
$-83.3M
Q2 25
$-70.0M
Q4 24
$-59.3M
$-6.8M
Q3 24
$-58.3M
$-10.0M
Q2 24
$-58.3M
$-6.3M
Q1 24
$-62.4M
$8.7M
Q4 23
$-115.4M
$13.5M
Q3 23
$-105.7M
$23.9M
Total Assets
GCTS
GCTS
HCWB
HCWB
Q4 25
$15.6M
Q2 25
$17.6M
Q4 24
$19.9M
$30.2M
Q3 24
$22.6M
$26.6M
Q2 24
$23.4M
$26.8M
Q1 24
$35.8M
$30.4M
Q4 23
$16.4M
$28.5M
Q3 23
$43.4M
$35.6M
Debt / Equity
GCTS
GCTS
HCWB
HCWB
Q4 25
Q2 25
Q4 24
Q3 24
Q2 24
Q1 24
0.95×
Q4 23
0.47×
Q3 23
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GCTS
GCTS
HCWB
HCWB
Operating Cash FlowLast quarter
$-7.2M
$-2.8M
Free Cash FlowOCF − Capex
$-8.5M
$-2.9M
FCF MarginFCF / Revenue
-1120.2%
-746.8%
Capex IntensityCapex / Revenue
167.3%
28.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GCTS
GCTS
HCWB
HCWB
Q4 25
$-7.2M
Q2 25
$-8.6M
Q4 24
$-2.3M
$-2.8M
Q3 24
$-4.6M
$-2.9M
Q2 24
$-9.6M
$-4.9M
Q1 24
$-14.4M
$-3.6M
Q4 23
$-907.0K
$-3.9M
Q3 23
$-1.5M
$-5.6M
Free Cash Flow
GCTS
GCTS
HCWB
HCWB
Q4 25
$-8.5M
Q2 25
$-8.7M
Q4 24
$-2.9M
Q3 24
$-4.7M
$-3.0M
Q2 24
$-4.9M
Q1 24
$-3.7M
Q4 23
$-954.0K
$-7.6M
Q3 23
$-1.6M
$-6.2M
FCF Margin
GCTS
GCTS
HCWB
HCWB
Q4 25
-1120.2%
Q2 25
-738.5%
Q4 24
-746.8%
Q3 24
-179.3%
-695.0%
Q2 24
-788.7%
Q1 24
-331.4%
Q4 23
-22.8%
-574.8%
Q3 23
-36.0%
-729.0%
Capex Intensity
GCTS
GCTS
HCWB
HCWB
Q4 25
167.3%
Q2 25
7.7%
Q4 24
28.7%
Q3 24
2.1%
8.7%
Q2 24
3.0%
Q1 24
11.5%
Q4 23
1.1%
280.6%
Q3 23
1.4%
73.9%
Cash Conversion
GCTS
GCTS
HCWB
HCWB
Q4 25
Q2 25
Q4 24
Q3 24
Q2 24
Q1 24
-19.04×
Q4 23
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons